printemailclick to share buttonfacebooktwitterlinkedin
Genitourinary Cancer Evidence-based Series (EBS) and Practice Guidelines (PG)
 

Genitourinary cancers include the kidney, bladder, and prostate.

The Genitourinary Disease Site Group (GU DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. The titles of the reports produced to date by the DSG are listed below, with links to the PDF versions of those reports.

The PEBC has a formal and standardized process to ensure the currency of each document. This process guides clinical experts to assess a document’s current status and relevance (please see the PEBC Assessment & Review Protocol for more information). A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance.  The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC ( ccopgi@mcmaster.ca ) or the lead author of the document.

Imaging

  • Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer
    Guideline 27-2: August 2015
    Status: CURRENT

Prostate Cancer

  • Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update
    Guideline 3-A-2016-1
    Status: CURRENT
    The clinical practice guideline is an ASCO-CCO collaboration, produced by a joint expert panel convened by the ASCO Clinical Practice Guidelines Committee and the CCO Program in Evidence-Based Care.
  • Bone Health and Bone-Targeted Therapies for Prostate Cancer
    Guideline 3-14 Version 2: September 2016
    Status: CURRENT
  • Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer
    3-15 Version 2 EBS: September 2014
    Status: CURRENT
    The clinical practice guideline is an ASCO-CCO collaboration, produced by a joint expert panel convened by the ASCO Clinical Practice Guidelines Committee and the CCO Program in Evidence-based Care.
  • Adjuvant Radiotherapy Following Radical Prostatectomy for Pathologic T3 or Margin-Positive Prostate Cancer
    3-17 EBS Version 3: May 2014
    Status: CURRENT
  • Kidney

    • The Use of Targeted Therapies in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Updated Guideline 2017
      Guideline 3-8-4 Version 2: May 2017
      Status: CURRENT

    Testis


    For Education and Information Purposes

    • Low-Dose Rate Brachytherapy for Patients with Low- or Intermediate-Risk Prostate Cancer
      3-10 Version 2 EBS: October 31, 2012
      This document has been retired and incorporated into 3-A-2016-1: Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    • Risk Reduction of Prostate Cancer with Drugs or Nutritional Supplements
    • Interleukin-2 in the Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma
    • Interferon-alpha in the Treatment of Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer
    • High Intensity Focused Ultrasound for Prostate Cancer
    • Management of Stage I Nonseminomatous Testicular Cancer
    • Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer
    • Use of Adjuvant Chemotherapy Following Cystectomy in Patients with Deep Muscle-Invasive Transitional Cell Carcinoma of the Bladder
    • Use of Neoadjuvant Chemotherapy in Transitional Cell Carcinoma of the Bladder
    • Surveillance Programs for Early Stage Nonseminomatous Testicular Cancer
    • Use of Strontium 89 in Patients with Endocrine-Refractory Carcinoma of the Prostate Metastatic to Bone
    • The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
    • The Use of Conformal Radiotherapy and the Selection of Radiation Dose in T1 or T2 Prostate Cancer
    • Use of Chemotherapy in Advanced Unresectable or Metastatic Transitional Cell Carcinoma of the Bladder or Urothelium
    • The Use of Bisphosphonates in Men with Hormone-Refractory Prostate Cancer

      Contact:
      Program in Evidence-Based Care (PEBC)
      McMaster University, Juravinski Site
      G Wing, 2nd Floor
      711 Concession Street
      Hamilton, Ontario, Canada
      L8V 1C3

      Phone: 905.527.4322 ext. 42822
      Fax: 905.526.6775
      Email: ccopgi@mcmaster.ca
Last modified: Tue, May 30, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?

YesNo